Anti-Fungal Drugs Market to Grow with a CAGR of 4.33% through 2030
Increasing number of antifungal drugs as over the counter and rising
consumption of antifungal drugs in developing regions is expected to drive the
Global Anti-Fungal Drugs Market growth in the forecast period, 2026-2030.
According to TechSci Research report, “Anti-Fungal Drugs Market – Global
Industry Size, Share, Trends, Competition Forecast & Opportunities,
2030”, the Global Anti-Fungal Drugs Market stood at USD 12.47 billion in
2024 and is anticipated to grow with a CAGR of 4.33% in the forecast period,
2026-2030. The antifungal drugs market is witnessing significant expansion due
to the growing prevalence of various fungal infections, including fungal nail
infections, ringworm, and more.
Moreover, the increasing demand for antifungal drugs as over the counter
(OTC) medications, the rising demand for generic antifungal drugs, the
escalating incidence of nosocomial infections worldwide, and the continuous
drug innovations such as the development of synthetic and semi-synthetic
azole-based compounds for the treatment of invasive fungal infections, among
others, will contribute to the surge in antifungal drug demand.
Browse over XX market data Figures spread through XX Pages and an
in-depth TOC on
"Global Anti-Fungal Drugs Market”
Market drivers, such as the increasing prevalence of fungal infections,
present significant growth opportunities for vendors. However, market
participants will face challenges due to factors like the rise of
multidrug-resistant fungal pathogens. To capitalize on these opportunities,
market vendors should prioritize growth prospects in fast-growing segments
while maintaining their positions in slow-growing segments.
Driving demand in the global antifungal drugs market is the growing
awareness of fungal infections and the rising instances of such infections due
to unhygienic environments in densely populated cities. The most prevalent
systemic fungal infection, systemic candidiasis, is expected to drive growth in
the coming years. The availability of various antifungal drugs and the
popularity of over-the-counter antifungal drugs for dermal infections have
positively impacted the market. Antifungal drugs play a crucial role in
inhibiting fungal cell wall development, disrupting cell membranes, and
preventing cell proliferation. The market for antifungal therapies includes
powders, drugs, pastes, and ointments. Azoles antifungal drugs currently hold a
dominant share in the market, driven by increasing awareness.
Additionally, the rising demand for antifungal powder contributes to the
market's revenue growth. Antifungal powder not only cures fungal infections but
also reduces itching, inhibits recurrence, and provides relaxing maintenance
therapy. These drugs help prevent and treat fungal skin infections caused by
sweat and moisture. Therefore, powder-form drugs are used to treat itching,
irritation, rashes, and swelling in various body parts containing Clotrimazole,
which effectively destroys fungi and drives revenue growth. In May 2022,
Bayer's Consumer Health division launched the new and improved Canesten
anti-fungal treatment solution in India, available in powder and cream forms.
These products possess anti-fungal characteristics that aid in the prevention
and treatment of skin infections.
Other factors contributing to market growth include favorable government
initiatives, corporate funds, and growing healthcare budgets in developing
economies. Technological advancements in diagnostic tests and devices have also
contributed to more accurate treatment, further fueling market growth. However,
the continued preference for conventional drugs and the high cost and side
effects of antifungal drugs poses challenges to their swift adoption.
Additionally, the diminishing efficacy of drugs due to increasing fungal
resistance is another market challenge to address.
The Global Anti-Fungal Drugs Market is segmented into drug class,
indication, infection type, route of administration, end user, distribution
channel, regional distribution, and company.
The
Echinocandins segment is anticipated to be the second most dominant drug class
during the forecast period due to several key factors. Echinocandins, including
drugs like caspofungin, micafungin, and anidulafungin, are highly effective
against a wide range of fungal infections, particularly Candida and Aspergillus
species. They offer a favorable safety profile and are generally
well-tolerated, making them a preferred option, especially in immunocompromised
patients. Their fungicidal activity against Candida species and fungistatic
action against Aspergillus contribute to their increasing clinical use.
Moreover, the rising incidence of invasive fungal infections and growing
resistance to older antifungal agents like azoles have further boosted demand.
Echinocandins are often used in hospital settings, especially in intensive care
units, which enhances their market share. Continued R&D efforts and
expanding indications for use also support growth in this segment, reinforcing
its strong position in the antifungal therapeutics market.
Europe is
projected to be the fastest-growing region in the antifungal drugs market
during the forecast period, driven by several key factors. The increasing
prevalence of fungal infections, especially among aging populations and
immunocompromised individuals, such as cancer patients and organ transplant
recipients, is a major growth driver. Rising awareness among healthcare
providers and patients regarding early diagnosis and treatment of fungal
infections has led to greater adoption of antifungal therapies across the
region.
Furthermore, the
European healthcare infrastructure is well-developed, with robust public and
private healthcare systems that support the availability and accessibility of
advanced antifungal treatments. Governments and healthcare agencies in
countries such as Germany, France, and the UK are investing in improving
infection control and hospital hygiene, which indirectly supports the demand
for effective antifungal agents.
In addition, the
European region has a strong pharmaceutical and biotechnology presence,
encouraging continuous research and development of new antifungal drugs.
Regulatory bodies such as the European Medicines Agency (EMA) provide
structured pathways for drug approvals, further facilitating market growth.
Collaborations between academia, hospitals, and pharmaceutical companies are
also fostering innovation. Combined with rising antimicrobial resistance and
the emergence of new fungal pathogens, these factors position Europe as the
fastest-growing market in the antifungal drugs landscape.
Major companies operating in Global Anti-Fungal Drugs Market
are:
- Abbott
Laboratories Inc.
- Astellas
Pharma Inc.
- Bayer AG
- GSK plc
- Glenmark
Pharmaceuticals Limited
- Merck
& Co. Inc.
- Novartis
AG
- Pfizer
Inc.
- Mycovia
Pharmaceuticals, Inc.
- Apex
Laboratories Pvt. Ltd.
Download Free Sample Report
Customers can also request for 10% free customization on this report.
“The increasing prevalence of fungal and nosocomial infections is a key
factor that contributes to a positive market outlook. Antifungal drugs
demonstrate efficacy against both systemic and superficial infections acquired
from exposure to contaminated surfaces in hospitals or humid conditions.
Furthermore, the convenient availability of over the counter (OTC) drugs in
urban and rural areas propels market growth. As health consciousness rises
among the masses, consumers increasingly choose OTC therapeutics for timely
treatment of minor infections. Moreover, product innovations, such as the
development of synthetic and semi-synthetic azole-based compounds for invasive
fungal infection treatment, serve as growth-inducing factors. Pharmaceutical
manufacturers invest extensively in research and development (R&D) of novel
therapeutics in the form of sprays, creams, tablets, and injections with
enhanced efficacy. Additionally, significant growth in the pharmaceutical
industry, coupled with favorable government policies promoting public health,
is anticipated to drive market growth.,” said Mr. Karan Chechi, Research
Director, TechSci Research, a research-based management consulting firm.
“Anti-Fungal Drugs Market Segmented By Drug Class (Azoles, Echinocandins,
Polyenes, Allylamines, Others), By Indication (Candidiasis, Aspergillosis,
Mucormycosis, Dermatophytosis, Others), By Infection Type (Superficial Fungal
Infection, Systemic Fungal Infection), By Route of Administration (Topical,
Oral, Parenteral, Others), By End User
(Homecare, Hospitals, Clinics, Others), By Distribution Channel (Retail
Pharmacy, Hospital Pharmacy, Online Pharmacy), By Region and Competition, Forecast &
Opportunities, 2020-2030F”,
has evaluated the future growth potential of Global Anti-Fungal Drugs Market
and provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Anti-Fungal Drugs Market.
Contact:
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States- 10170
Tel: +1-332-258-6602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com